View Older Stories

Feb 19, 2026 10:34AM Corcept Therapeutics (CORT) Drop Said Tied to Chatter it Lost Case Against Teva Pharma (TEVA)

Jan 23, 2026 06:45AM Corcept Therapeutics (CORT) PT Raised to $105 at H.C. Wainwright

Jan 23, 2026 06:35AM Corcept Therapeutics (CORT) PT Raised to $100 at Canaccord Genuity

Jan 13, 2026 09:44AM CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Jan 2, 2026 06:35AM Corcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright

Jan 2, 2026 06:22AM Corcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity

Dec 31, 2025 03:15PM Corcept Therapeutics (CORT) call put ratio 1 call to 2.4 puts as share price down 51%

Dec 31, 2025 12:36PM Corcept Therapeutics (CORT) PT Lowered to $50 at Truist Securities

Dec 31, 2025 09:46AM Wolfe Research Downgrades Corcept Therapeutics (CORT) to Underperform

Dec 31, 2025 08:00AM Corcept receives FDA rejection for relacorilant hypercortisolism treatment

Dec 31, 2025 06:01AM Increasing unusual put option volume: SLS AMT IEP HLF ARCC CORT HELE FVRR NOW GNRC ADP

Dec 16, 2025 12:59AM UBS Starts Corcept Therapeutics (CORT) at Neutral

Nov 25, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)

Nov 17, 2025 04:12PM Wolfe Research Starts Corcept Therapeutics (CORT) at Peerperform

Nov 4, 2025 04:07PM Corcept Therapeutics (CORT) Tops Q3 EPS by 3c, provides guidance

Oct 14, 2025 08:00AM Corcept submits European application for ovarian cancer treatment

Oct 6, 2025 04:39PM Corcept Therapeutics board member Cannon resigns effective Oct. 10

Oct 6, 2025 08:53AM Truist Securities Reiterates Buy Rating on Corcept Therapeutics (CORT)

Sep 22, 2025 02:32PM Corcept to present ROSELLA trial data on ovarian cancer at ESMO 2025

Aug 1, 2025 09:22AM Corcept Therapeutics (CORT) PT Lowered to $121 at Piper Sandler

Jul 31, 2025 04:17PM Corcept Therapeutics (CORT) Tops Q2 EPS by 10c ; Offers Guidance

Jul 14, 2025 08:03AM Corcept submits drug application for ovarian cancer treatment

Jul 11, 2025 09:45AM Piper Sandler Reiterates OW Rating on Corcept Therapeutics (CORT) Following Expert Call

Jun 26, 2025 08:28AM Truist on Corcept Therapeutics (CORT): 'Risk/Reward Still Favorable'

Jun 23, 2025 04:31PM Corcept Therapeutics (CORT) presents data from CATALYST trial of Korlym

Jun 5, 2025 06:15AM Corcept Therapeutics (CORT) Presents Results from Phase 2 Study of Dazucorilant

Jun 3, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)

Jun 2, 2025 11:15AM Corcept Therapeutics (CORT) Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet

May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025

May 6, 2025 08:39AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)

May 6, 2025 07:12AM Corcept Therapeutics (CORT) PT Lowered to $145 at H.C. Wainwright

May 5, 2025 04:09PM Corcept Therapeutics (CORT) Tops Q1 EPS by 2c, provides guidance

Apr 23, 2025 03:20PM Corcept Therapeutics (CORT) call put ratio 20 calls to 1 put with a focus on May 75 calls and June 80 calls as share price up 7.3%

Apr 21, 2025 08:01AM Corcept Therapeutics (CORT) Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial

Apr 7, 2025 08:01AM Corcept Therapeutics (CORT) Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Apr 3, 2025 07:38AM Corcept Therapeutics (CORT) PT Raised to $131 at Piper Sandler Post-ROSELLA

Apr 1, 2025 08:13AM Corcept Therapeutics (CORT) PT Raised to $150 from $76 at Truist on 'Positive Ph3 ROSELLA Data'

Apr 1, 2025 06:45AM Corcept Therapeutics (CORT) PT Raised to $150 at H.C. Wainwright

Mar 31, 2025 02:23PM Corcept Therapeutics (CORT) April 110 calls and April 80 puts active as share price up 95%

Mar 31, 2025 10:52AM Increasing unusual call option volume: XLI UMC MCHI FEZ DT ULCC MGA ZH TDS LXRX DESP CORT

Mar 31, 2025 08:02AM Corcept Therapeutics (CORT): Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Mar 3, 2025 04:08PM Corcept Therapeutics (CORT): FDA Files New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Feb 26, 2025 04:09PM Corcept Therapeutics (CORT) Misses Q4 EPS by 12c, provides guidance

Feb 11, 2025 06:42AM Corcept Therapeutics (CORT) PT Raised to $115 at H.C. Wainwright

Feb 7, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)

Jan 30, 2025 06:27AM Corcept Therapeutics (CORT) PT Raised to $130 at Canaccord Genuity

Dec 30, 2024 05:26PM Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm

Dec 30, 2024 05:16PM Corcept Therapeutics (CORT) Submits NDA for Relacorilant as a Treatment for Patients With Hypercortisolism

Dec 16, 2024 08:06AM Corcept Therapeutics' (CORT) Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Dec 12, 2024 04:05PM Corcept Therapeutics (CORT) Reports Positive Results in Treatment Phase of CATALYST Trial

View Older Stories